Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...
On remand from the Federal Circuit, the Patent Trial and Appeal Board on Thursday reaffirmed its decision that The Broad ...
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results